Serina Therapeutics Regains Compliance with NYSE American Listing Standards

Serina Therapeutics has announced that NYSE American has accepted the company's plan to regain compliance with continued listing standards. The company received a notice in January 2026 for non-compliance with NYSE American Company Guide Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii). Serina will now have until July 9, 2027, to regain conformity with continued listing standards and will continue to be listed on NYSE American during this time. The company will be subject to quarterly monitoring by NYSE American for compliance with the plan.